Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bit Digital Inc (BTBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bit Digital Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Bit Digital Inc trades at $1.47 (market cap $471.05M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 62.8× Bit Digital Inc's market cap. Which is the better fit depends on your goals.
| ALNY | BTBT | |
|---|---|---|
Market Cap | $29.60B | $471.05M |
Sector | Health | Technology |
52-Week High | $491.22 | $4.22 |
52-Week Low | $205.48 | $1.23 |
Enterprise Value | $27.56B | $760.36M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
BTBT trades at $1.46, up 12.31% today, but the technical outlook is bearish with selling pressure outweighing buying signals. Fundamentally, the company reported a net loss of $80.32 million in 2025, with a negative net income margin of -145.45% in 2026, indicating severe profitability challenges despite a gross margin above 55%. Recent earnings have missed expectations in two of the last three quarters.
The outlook remains challenged by persistent losses and negative cash flow from operations. While analyst coverage is limited and currently shows a 100% buy rating from two firms, significant execution risk and reliance on financing activities to offset operational cash burns present substantial headwinds for shareholder value appreciation in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →
